CL2021001058A1 - Proteínas heterodiméricas fusionadas con fc - Google Patents

Proteínas heterodiméricas fusionadas con fc

Info

Publication number
CL2021001058A1
CL2021001058A1 CL2021001058A CL2021001058A CL2021001058A1 CL 2021001058 A1 CL2021001058 A1 CL 2021001058A1 CL 2021001058 A CL2021001058 A CL 2021001058A CL 2021001058 A CL2021001058 A CL 2021001058A CL 2021001058 A1 CL2021001058 A1 CL 2021001058A1
Authority
CL
Chile
Prior art keywords
heterodimeric
fused proteins
fused protein
protein constructs
fused
Prior art date
Application number
CL2021001058A
Other languages
English (en)
Inventor
Ann F Cheung
Jean-Marie Cuillerot
Asya Grinberg
Eva Gutierrez
William Haney
Nicolai Wagtmann
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of CL2021001058A1 publication Critical patent/CL2021001058A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Constructos de proteínas fusionadas con Fc, como dímeros monovalentes tienen semivida en suero más alta, con títulos más altos de las proteínas durante la producción, mayor estabilidad durante el almacenamiento, y eficacia mejorada como agente terapéutico; Constructos de proteínas fusionadas con Fc con mutaciones en la región Fc que reducen las funciones efectoras, con una actividad incrementada para inhibir el crecimiento tumoral, ventajoso en el tratamiento contra el cáncer.
CL2021001058A 2018-10-23 2021-04-23 Proteínas heterodiméricas fusionadas con fc CL2021001058A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862749489P 2018-10-23 2018-10-23
US201862781898P 2018-12-19 2018-12-19
US201962788499P 2019-01-04 2019-01-04
US201962827347P 2019-04-01 2019-04-01
US201962895889P 2019-09-04 2019-09-04

Publications (1)

Publication Number Publication Date
CL2021001058A1 true CL2021001058A1 (es) 2021-11-12

Family

ID=68583501

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021001058A CL2021001058A1 (es) 2018-10-23 2021-04-23 Proteínas heterodiméricas fusionadas con fc
CL2022000900A CL2022000900A1 (es) 2018-10-23 2022-04-08 Proteínas heterodiméricas fusionadas con fc. (divisional de solicitud 202101058)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000900A CL2022000900A1 (es) 2018-10-23 2022-04-08 Proteínas heterodiméricas fusionadas con fc. (divisional de solicitud 202101058)

Country Status (17)

Country Link
US (2) US20220119533A1 (es)
EP (1) EP3870598A1 (es)
JP (1) JP2022505871A (es)
KR (1) KR20210080460A (es)
CN (1) CN113286808A (es)
AU (1) AU2019366956A1 (es)
BR (1) BR112021007175A2 (es)
CA (1) CA3117212A1 (es)
CL (2) CL2021001058A1 (es)
CO (1) CO2021006474A2 (es)
IL (1) IL281954A (es)
MA (1) MA53982A (es)
MX (1) MX2021004711A (es)
PE (1) PE20211279A1 (es)
SG (1) SG11202104136YA (es)
TW (1) TW202033547A (es)
WO (1) WO2020086758A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
CN110267977A (zh) 2016-08-10 2019-09-20 亚洲大学校产学协力团 细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
KR20200118824A (ko) * 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
BR112021005907A2 (pt) 2018-09-27 2021-08-10 Xilio Development, Inc. citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
JP2022505871A (ja) 2018-10-23 2022-01-14 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質
CA3151574A1 (en) * 2019-09-27 2021-04-01 Dhan Sidhartha CHAND Heterodimeric proteins
CN115916233A (zh) 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
EP4133085A1 (en) 2020-04-10 2023-02-15 CytomX Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4138778A1 (en) * 2020-04-22 2023-03-01 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
CN115803091A (zh) * 2020-05-22 2023-03-14 福迈康股份公司 Ace2-fc融合蛋白及其用途
MX2023004933A (es) * 2020-10-29 2023-06-06 Formycon Ag Proteinas de fusion de ace2 y usos de las mismas.
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
AU2022315528A1 (en) * 2021-07-22 2023-10-19 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
WO2023025129A1 (zh) * 2021-08-24 2023-03-02 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
EP4419545A2 (en) 2021-10-20 2024-08-28 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
CA3234552A1 (en) * 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024073483A2 (en) * 2022-09-28 2024-04-04 The General Hospital Corporation 4-1bbl and il-12 therapy for treatment of glioblastoma
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
WO2024094755A1 (en) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
GB9022040D0 (en) 1990-10-10 1990-11-21 Biopharm Ltd Platelet adhesion inhibitor
US5851794A (en) 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2117780A1 (en) 1992-04-10 1993-10-28 Paul F. Goetinck Cartillage matrix protein and methods for use
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
CA2255669A1 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
WO2000021989A1 (en) 1998-10-09 2000-04-20 Medimmune, Inc. Decorin binding proteins dbp a and b and genes encoding them
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1163253A2 (en) 1999-03-15 2001-12-19 The General Hospital Corporation Syndesmos and uses thereof
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6908994B1 (en) 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
WO2000077041A2 (en) 1999-06-16 2000-12-21 The Texas A & M University System Peptides from decorin binding protein and their uses
AU5622800A (en) 1999-06-18 2001-01-09 Med Immune, Inc. Combined decorin binding protein and outer surface protein compositions and methods of use
WO2001043763A1 (en) 1999-12-15 2001-06-21 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
US6517838B1 (en) 2000-06-16 2003-02-11 The Texas A&M University System Decorin binding protein essential peptides and methods of use
US20020055488A1 (en) 2000-09-21 2002-05-09 Wessels Michael R. Prevention and treatment of streptococcal and staphylococcal infection
PT1411118E (pt) 2001-06-22 2008-12-09 Chugai Pharmaceutical Co Ltd Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
GB0406415D0 (en) 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
JP4730304B2 (ja) 2004-05-20 2011-07-20 和光純薬工業株式会社 ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法
WO2005124356A2 (en) 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein cbp2 as a marker for colorectal cancer
NZ579543A (en) 2004-07-09 2011-07-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
US7820401B2 (en) 2004-08-23 2010-10-26 Albert Einstein College Of Medicine Of Yeshiva University Collagen VI and cancer
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
JP5140579B2 (ja) 2005-06-08 2013-02-06 カンジェーン コーポレイション 病原菌に対する生体防御を増強するヒアルロン酸結合性ペプチド
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
EP1864996A1 (en) 2006-06-06 2007-12-12 Helmholtz-Zentrum für Infektionsforschung GmbH Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker.
HU0600578D0 (en) 2006-07-13 2006-09-28 Szilak Labor Bioinformatikai E Nuclear protein transport
CA2660455A1 (en) 2006-08-08 2008-02-14 Seikagaku Corporation Method for determination of molecular weight of hyaluronic acid
WO2008089448A2 (en) 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
SI2178921T1 (sl) 2007-07-17 2016-05-31 E.R. Squibb & Sons, L.L.C. Monoklonska protitelesa proti glipikan-3
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
AU2009226423B2 (en) 2008-03-17 2014-11-27 Chugai Seiyaku Kabushiki Kaisha Method for detection of liver cancer cell using anti-glypican-3 antibody
US20090297479A1 (en) 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
AU2009231991B2 (en) 2008-04-02 2014-09-25 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
EP2270145B1 (en) 2008-04-15 2013-01-16 Wako Pure Chemical Industries, Ltd. Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
WO2010033866A2 (en) 2008-09-19 2010-03-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
GB0818273D0 (en) 2008-10-06 2008-11-12 Cambridge Entpr Ltd Modulation of cellular activity and differentiation
KR101105428B1 (ko) 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
CA2757531A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
US20120100106A1 (en) 2009-05-04 2012-04-26 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
WO2011020783A2 (en) 2009-08-17 2011-02-24 Roche Glycart Ag Targeted immunoconjugates
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
EP2640740B1 (en) 2010-11-15 2017-03-15 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
TW202323302A (zh) * 2010-11-30 2023-06-16 日商中外製藥股份有限公司 細胞傷害誘導治療劑
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
UA117294C2 (uk) * 2011-02-10 2018-07-10 Рош Глікарт Аг Імунокон'югат
ES2692268T3 (es) 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR102006036B1 (ko) 2011-05-24 2019-07-31 시믹 아이피, 엘엘씨 히알루론산-결합 합성 펩티도글리칸 및 이의 제조 및 이용 방법
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
PL3351261T3 (pl) * 2011-10-11 2021-12-06 Universität Zürich Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
EP2804586A4 (en) 2012-01-19 2016-03-16 Univ Johns Hopkins BIOMATERIALS COMPRISING HYALURONIC ACID-BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMER MOLECULES FOR HYALURONIC ACID RETENTION AND TISSUE ENGINEERING APPLICATIONS
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
WO2013163766A1 (en) 2012-05-04 2013-11-07 Cangene Corporation ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
PL2880170T3 (pl) 2012-08-02 2017-02-28 F.Hoffmann-La Roche Ag SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
KR20150037959A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
SG10201800535XA (en) 2012-08-07 2018-02-27 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
ES2773107T3 (es) * 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
KR101522954B1 (ko) 2012-11-27 2015-05-27 아주대학교산학협력단 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
LT2970422T (lt) * 2013-03-15 2018-06-25 F. Hoffmann-La Roche Ag Il-22 polipeptidai ir il-22 su fc sulieti baltymai bei panaudojimo būdai
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP2970435B1 (en) 2013-03-15 2020-08-12 Eli Lilly and Company Methods for producing fabs and bi-specific antibodies
JP6618893B2 (ja) 2013-04-29 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
US20160032007A1 (en) 2014-04-28 2016-02-04 Duke University Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
EP4306544A3 (en) 2014-05-06 2024-03-20 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
US10519234B2 (en) 2014-06-27 2019-12-31 Innate Pharma NKp46 binding proteins
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
BR112017006178A2 (pt) 2014-11-06 2018-05-02 F. Hoffmann-La Roche Ag região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
JP6576456B2 (ja) 2014-11-06 2019-09-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種
WO2016077638A1 (en) 2014-11-12 2016-05-19 Memorial Sloan Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
US10124038B2 (en) 2015-03-20 2018-11-13 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
WO2016164429A1 (en) 2015-04-06 2016-10-13 The General Hospital Corporation Anti-cspg4 chimeric antigen receptors
JP6762485B2 (ja) 2015-06-24 2020-09-30 学校法人慶應義塾 抗グリピカン−１−免疫抗原受容体
RS62151B1 (sr) * 2015-08-07 2021-08-31 Alx Oncology Inc Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
CA2998584A1 (en) 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
US10584160B2 (en) 2015-09-23 2020-03-10 Bristol-Myers Squibb Company Glypican-3-binding fibronectin based scaffold molecules
RU2770001C2 (ru) 2015-10-06 2022-04-14 Риджентс Оф Дзе Юниверсити Оф Миннесота Терапевтические соединения и способы
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
EP3494135A1 (en) 2016-08-02 2019-06-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
CN110267977A (zh) 2016-08-10 2019-09-20 亚洲大学校产学协力团 细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
KR101928981B1 (ko) * 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
RU2019114175A (ru) * 2016-10-14 2020-11-16 Ксенкор, Инк. Биспецифические гетеродимерные слитые белки, содержащие fc-слитые белки il-15/il-15ra и фрагменты антитела к pd-1
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN110831634B (zh) 2017-03-08 2024-07-02 密歇根大学董事会 磷脂酰肌醇蛋白聚糖-3肽试剂和方法
TW201900673A (zh) 2017-03-27 2019-01-01 瑞士商赫孚孟拉羅股份公司 改良之抗原結合受體
US11242403B2 (en) 2017-04-26 2022-02-08 Mitsubishi Tanabe Pharma Corporation Syndecan-1 (CD138) binding agents and uses thereof
EP3617231A4 (en) 2017-04-28 2021-04-07 National University Corporation Kochi University ANTI-GPC-1 ANTIBODY
CN111010866A (zh) * 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
JP2019014449A (ja) 2017-07-10 2019-01-31 トヨタ自動車株式会社 車両用動力伝達装置
WO2019051308A1 (en) 2017-09-07 2019-03-14 Dragonfly Therapeutics, Inc. NKG2D, CD16 BINDING PROTEINS AND ANTIGEN ASSOCIATED WITH A TUMOR
BR112020005035A2 (pt) * 2017-09-21 2020-09-15 Merck Patent Gmbh proteína de fusão comprendendo porção fgf-18
IL310960A (en) * 2017-09-22 2024-04-01 Wuxi Biologics Ireland Ltd New bispecific polypeptide complexes
EP3697441B1 (en) 2017-10-20 2023-06-07 F. Hoffmann-La Roche AG Method for generating multispecific antibodies from monospecific antibodies
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
DE102018208278A1 (de) 2018-05-25 2019-11-28 Robert Bosch Gmbh Betriebsassistenzverfahren, Steuereinheit, Betriebsassistenzsystem und Arbeitsvorrichtung
CA3106212A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
US11358999B2 (en) * 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
JP2022505871A (ja) * 2018-10-23 2022-01-14 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質

Also Published As

Publication number Publication date
US20220119533A1 (en) 2022-04-21
MX2021004711A (es) 2021-07-02
BR112021007175A2 (pt) 2021-08-10
CL2022000900A1 (es) 2023-01-20
AU2019366956A1 (en) 2021-05-20
CN113286808A (zh) 2021-08-20
CA3117212A1 (en) 2020-04-30
PE20211279A1 (es) 2021-07-19
KR20210080460A (ko) 2021-06-30
EP3870598A1 (en) 2021-09-01
MA53982A (fr) 2022-01-26
TW202033547A (zh) 2020-09-16
US11787864B2 (en) 2023-10-17
JP2022505871A (ja) 2022-01-14
US20230033425A1 (en) 2023-02-02
SG11202104136YA (en) 2021-05-28
IL281954A (en) 2021-05-31
WO2020086758A8 (en) 2021-05-06
WO2020086758A1 (en) 2020-04-30
CO2021006474A2 (es) 2021-06-10

Similar Documents

Publication Publication Date Title
CL2021001058A1 (es) Proteínas heterodiméricas fusionadas con fc
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
IL272105A (en) Local administration of pharmaceutical agents containing cell-penetrating peptides for use in the treatment of age-related macular degeneration and other eye diseases
CY1122282T1 (el) Μεθοδοι και συνθεσεις για παραδοση στο κνς της αρυλοσουλφατασης α
CO2018005215A2 (es) Construcciones específicas del hígado para expresión del factor viii
CL2017002488A1 (es) Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012)
PH12020551818A1 (en) Gene therapy constructs and methods of use
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
CL2019003496A1 (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
MX2015014773A (es) Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
CY1122508T1 (el) Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
CL2022000115A1 (es) Terapia genética cardíaca con aav para la cardiomiopatía en humanos.
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
CO2019003865A2 (es) Proteína terapéutica
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.
AR116920A1 (es) Proteínas de fusión heterodimérica fc
WO2017143104A8 (en) Modulation of hypoxia associated with stroke